PRESS PLAY
Welcome to the ZS podcast! In this episode, we’re discussing CAR T-cell therapy with Dr. Sridevi Rajeeve and Todd Greenwood. We’ll explore the challenges of this treatment and how remote patient monitoring could revolutionize it. Stay tuned for an enlightening conversation on making cancer treatment more accessible and cost-effective.
Based on 6 episodes we listened to · September 2026
ZS Podcast makes healthcare innovation concrete by tracing how data, organizational culture, commercial strategy, and partnerships shape what can actually scale.
ZS Podcast keeps returning to the machinery behind healthcare innovation: pharma commercial models, connected health, organizational change, and partnerships between drugmakers and technology companies.
A pharma launch deck meets its least convenient question: what does the physician actually need?
Press play if you want
Short reviews from the PlayNext desk, based on the episodes we processed.
A clear look at culture, structure, and the hard part of scaling innovation.
This episode lays out a straightforward argument: organizations can keep doing today’s work and still make room for new models, but only if structure and culture pull together.
A reset on pharma marketing as hybrid engagement and customer-centric thinking take center stage.
The piece treats pharma marketing as a shift away from an old, sales-first, face-to-face playbook and toward something more customer-led and hybrid.
A steady look at connected health, access, pharmacists, and the limits of technology alone.
The discussion treats connected health through a biopharma lens and keeps coming back to a simple point: technology can help, but it cannot carry the load on its own.
A sober look at why innovation gets absorbed when the core business takes over.
Transforming Biopharma returns to a familiar problem: innovation is simple to celebrate, but much harder to sustain when culture, structure, metrics, and operating models all have to line up.
A clear case for turning fragmented pharma data into usable customer context.
It frames pharma marketing as a problem of context, not just collection: understanding the signals around who physicians are, what their offices can handle, and why the next move should matter.
A practical look at how pharma and health tech partners build trust, share responsibility, and learn by doing.
This episode presents pharma and health tech partnerships as something closer to a working relationship than a simple vendor deal. Its clearest point is that both sides need intellectual honesty about what pharma can do well, what should be handled by partners, and why the work…
A clear look at how pharma and digital health partners build trust without making the work feel one-sided.
The conversation stays focused on a practical tension: a pharma company and a digital health partner have to trust each other, share control, and treat the relationship as more than a short project.
A healthcare data-strategy conversation that connects analytics, operations, and patient outcomes.
This episode uses Mahmoud Majeed's move from architecture into healthcare strategy to frame a practical question: how do healthcare companies turn data into better decisions, smoother operations, and new value?
Peter Attia evaluates longevity science, from CETP inhibitors to protein debates, through evidence.
Morning medical evidence, compressed for practice.
Medical research, translated through patient experience.
Mahmoud Majeed, a leader at consulting firm ZS, discusses how data and technology can connect a fragmented healthcare system.
A roundtable discussion hosted by HIMSS explores the growing trend of partnerships between pharmaceutical companies and health tech firms.
Pharma has spent too much time on the what.
Maria Whitman starts with a practical tension.
Maria Whitman opens with a blunt premise: structure alone cannot carry culture.
The episode looks at how pharmaceutical marketing has moved from a sales-first model to a more customer-focused one.
Maria Whitman opens by asking how organizations can keep changing while still running today's business.
A roundtable discussion explores the strategic partnership between Keezy Pharmaceuticals and Kaya Health, examining the opportunities and challenges of pharma-health tech collaborations.